A short discussion of the unmet needs of CLL patients
Decitabine dosing regimens in older AML patients: 5-day vs. 10-day, is there a difference?
The challenges of studying the progression and biology of myeloma
A follow-up from the CASTOR trial evaluating daratumumab with bortezomib for the treatment of MM
Frontline treatment of elderly multiple myeloma patients and management of relapse/refractory
Enrique Ocio et al.